Someone has to sell it.
IDENTIFY
DEMONSTRATE VALUE
ENGAGE
PITCH
NAVIGATE
NEGOTIATE
CLOSE
Scientific progress doesn't reach patients by itself. It requires a dedicated commercial engine to bridge the gap between innovation and impact.
Commercial Execution
- Strategy through close and transition to implementation
- Commercial story building and market engagement
- Advanced negotiation and contracting support
- End-to-end commercial engine development
Capital Readiness
- Investment thesis and financial modeling
- Investor strategy and data room preparation
- Capital readiness and financing support
- Compliance and regulatory strategy
Strategy → Execution → Customers → Revenue → Investment readiness → Capital → Patient impact
Vision alone yields no results. Action does.
Accountability Scoreboard
Verifying commercial routes for cancer solutions.
Executive Engagement
Directly bridging business plans with leadership targets.
Strategic Partnerships
Forging essential networks to catalyze market expansion.
Commercial Agreements
Crafting agreements that ensure income and safeguard breakthroughs.
Revenue Acceleration
Quantifiable increases via tactical commercial fulfillment.
Financing Readiness
Investor narratives and repositories to secure funding.
Business Plan Fidelity
Monitoring vital benchmarks to guarantee ownership. We are engaged to create measurable progress.
Commercial Pathway
Define Market
Identify segment and populations where innovation provides max value.
Build Story
Narrative bridging scientific discovery and adoption impact.
Identify Opps
Map commercial channels and partnerships for market entry.
Engage Market
Initiate KOL engagement to demonstrate value and build trust.
Advance Opp
Refine commercial approach based on early market feedback.
Negotiate
Finalize terms that protect innovation and secure resources.
Transition
Ensure seamless handover to manage new revenue streams.
Scale Engine
Establish repeatable models across oncology segments for scale.
Capital Strategy
Opportunity
- Investment Thesis
- Market Opportunity
- Commercial Model
- Financial Projections
Materials
- Data Room Strategy
- Financial Modeling
- Investor Deck
- Commercial Narrative
Audience
- VC Partners
- Strategic Investors
- Private Equity
- Founders & Boards
Compensation: Helix is not compensated based on capital raised. We are engaged to create measurable progress and commercial momentum.
Process
- Due Diligence
- Investor Strategy
- Capital Readiness
- Execution Roadmap
Who We Serve
Seed Stage Innovators
Founders navigating the first commercial intersection.
Early Commercial Scale
Teams transitioning from clinical validation to revenue.
Health Tech Startups
Specialized oncology software and diagnostic firms.
AI & Health Data
Companies leveraging machine learning for patient impact.
Theranostics
Developers of targeted therapies and imaging agents.
Clinical Research
Specialists in RWE and real-world evidence generation.
Delivery & Care
Organizations focused on precision delivery and care coordination.
Molecular Diagnostics
Companies focused on diagnostic and early detection technologies.
Why Helix
Execution over recommendations
We focus on the seven-chip sequence from identification to close, ensuring every step is carried through to commercial reality.
Accountability to the number
We are engaged to create measurable progress, not just to create activity. Our scoreboard honesty is built into our operating model.
Elastic executive capacity
Our senior operators provide the necessary capacity to scale alongside your oncology innovation, carrying the bag through execution.
End-to-end ownership
We take the number and stay through execution. We are not compensated to create activity; we are engaged to create measurable progress.
Senior operators in the work
Michael brings 30 years of executive leadership to the table, ensuring that the commercial and capital strategy is integrated from day one.
Commercial and capital integration
We bridge the gap between clinical innovation and capital readiness, providing the investor strategy and data room required for growth.
Oncology specialization
Our expertise is rooted in the oncology sector, allowing us to navigate the complex commercial pathways of precision diagnostics and AI.
Persistence with candour
We stay through execution with candour. We are not a traditional advisory firm; we are a partner committed to the patient impact.
OPERATING RECORD
Experience Behind The Engagement
$100M+
Enterprise oncology contracts closed
$120M+
Financing supported as strategic leader
30 Years
Across cancer care, industry and health tech
These figures reflect Michael G. Power's career to date, prior to and apart from Helix Cancer Strategies Inc. Client names are published with written approval.
Former Cancer Center Executive, CEO of Research Institute, Global Business Development Head, and Oncology Health-Tech CEO
I am a senior executive with over 30 years of leadership in the oncology sector. My career is defined by a commitment to commercial execution and capital readiness, having successfully led a comprehensive cancer center, closed over $100M in enterprise oncology contracts, and supported $120M in financing in both the public and private sectors. I bring a methodical, operator-driven approach to the commercialization of health tech, ensuring that scientific progress translates into measurable patient impact.
Michael G. Power, B.A., M.I.M, Managing Partner and Founder
“Innovators don't need more advice. They need senior business development capacity alongside their own team. Helix provides experienced operators who carry the bag, take the number, and stay through execution.”
COMMERCIAL EXECUTION
Strategy through close and transition to implementation.
CAPITAL READINESS
Investment thesis, model, and data room strategy.
MARKET ENGAGEMENT
Navigating complex oncology commercial landscapes.
COMMERCIAL STORY
Building a compelling narrative for growth.
INVESTOR STRATEGY
Direct engagement with capital markets.
REVENUE ENGINE SCALE
Scaling from strategy to a functioning engine.
Our Vision
To be the definitive commercial and capital partner for oncology innovators, driving measurable patient impact through high-stakes execution.
Our Mission
We help oncology innovators win customers, generate revenue, and achieve capital readiness to scale their impact.
Patients First
Every commercial strategy is anchored in the ultimate goal of improving patient outcomes and quality of life.
Execution Strategy
We prioritize actionable execution over theoretical recommendations, ensuring every strategy leads to measurable results.
Own the Outcome
We take full ownership of the commercial pathway, from initial engagement to the final revenue close.
Evidence Before Assertion
We demand clinical evidence and data-backed insights before making any strategic or commercial assertion.
Results Accountability
We establish the scoreboard upfront—clear KPIs, measurable outcomes, and accountability for delivering against them.
Carry the Bag
We are engaged to create measurable progress, not just to create activity, taking the lead through execution.
Meaningful Partnerships
We build long-term relationships based on shared success and by establishing deep and long lasting friendships.
Earn the Next Engagement
We are only compensated for measurable progress, ensuring our work is driven by results, not incentives.
We carry a bag. We deliver the number.
We join your business and stay through commercial execution. Helix Cancer Strategies Inc. is available for commercial and capital readiness assessments because it's all about delivering the number.
info@helixcancerstrategies.com